NICE recommends abemaciclib with fulvestrant for advanced HR+/HER2- breast cancer

NICE recently released draft guidance recommending abemaciclib (Verzenios®) with fulvestrant (Faslodex®) for patients with locally advanced or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer previously treated with endocrine therapy. The aim of locally advanced or metastatic breast cancer treatment is to delay progression and extend survival, rather than provide cure. After initial endocrine therapy, patients can be offered exemestane (Aromasin®) plus everolimus (Zortress® or Certican®), or a CDK4/6 inhibitor with fulvestrant. Abemaciclib is a CDK4/6 inhibitor, taken as a twice-daily pill, and succeeds two other NICE-recommended CDK4/6 inhibitors available through the Cancer Drugs Fund; ribociclib (Kisqali®) and palbociclib (Ibrance®). The...